Abstract: A purified preparation of an anti-CDW52 antibody which exhibits on size exclusion chromatography: a single peak under non-reducing conditions and two major peaks under reducing conditions.The preparation preferably also exhibits on conventional SDS PAGE: one main band using a non-reduced sample and two main bands using a reduced sample.Additionally the preparation exhibits on reversed phase HPLC: a single sharp peak under non-reducing conditions and two major peaks under reducing conditions. Also a process of purifying an anti-CDW52 antibody, formulations containing such a purified preparation and uses thereof.

Abstract: The present invention relates to the P.195 gene of Plasmodium falciparum and, more specifically, to the cloning of that gene. The invention further relates to a method of producing the P.195 protein using the cloned gene. The invention also relates to a vaccine comprising the P.195 protein and to the use of same in the prophylaxis of malaria.

Abstract: Potentiating agents which enhance the efficacy of antineoplastic agents are disclosed. The potentiating agents disclosed are dibenz[b,e]oxepins such as doxepin.

Abstract: The present invention provides novel antigenic preparations comprising proteinaceous material associated with adenylate cyclase activity in cultures of B. pertussis, the said preparations being useful as components of acellular whooping cough vaccines. The invention further provides methods for the isolation of such antigenic preparations.

Abstract: Potentiating agents which enhance the efficacy of antineoplastic agents are disclosed. The potentiating agents disclosed are 2-(aminoethylamino) pyridines such as (E)-3-(6-(N-(2-Dimethylaminoethyl)-4-methoxybenzylamino)-2-pyridyl)acrylic acid.

Abstract: Potentiating agents which enhance the efficacy of antineoplastic agents are disclosed. The potentiating agents disclosed are acrivastine esters and the pharmaceutically acceptable salts thereof.

Abstract: Potentiating agents which enhance the efficacy of antineoplastic agents are disclosed. The potentiating agents disclosed are piperazinyl benzyl compounds such as 1-[.alpha.-(4-chlorophenyl)-3-methoxybenzyl]-4-allylpiperazine dihydrochloride.

Abstract: Potentiating agents which enhance the efficacy of antineoplastic agents are disclosed. The potentiating agents disclosed are acrivastine esters and the pharmaceutically acceptable salts thereof.

Abstract: Potentiating agents which enhance the efficacy of antineoplastic agents are disclosed. The potentiating agents disclosed are 2-(aminoethylamino) pyridines such as (E)-3-(6-(N-(2-Dimethylaminoethyl)-4-methoxybenzylamino)-2-pyridyl)acrylic acid.

Abstract: Potentiating agents for combatting multiple drug resistance of susceptible tumor cells in a subject in need of such treatment are disclosed. The potentiating agents disclosed are triprolidine, cis-triprolidine, and pharmaceutically acceptable salts thereof.

Abstract: Acaricidal compositions comprising a pyrethroid of formula ##STR1## wherein Z and Z.sup.1 are the same or different and each is halo and wherein X is hydrogen or cyano, provided that when Z and Z.sup.1 are both chloro, X must be cyano together with at least one organophosphorus compound, formulations containing them and their use for the control of veterinary ectoparasites of the sub-Orders Ixodoidea and Sarcoptiformes.